Sulkowski M.S.Chuang W.-L.JIA-HORNG KAOYang J.C.Gao B.Brainard D.M.Han K.-H.Gane E.2021-09-042021-09-0420161058-4838https://www.scopus.com/inward/record.uri?eid=2-s2.0-84994500704&doi=10.1093%2fcid%2fciw507&partnerID=40&md5=075364231a42a44f4fc05db584a16185https://scholars.lib.ntu.edu.tw/handle/123456789/581897Postmarketing cases of hepatitis B virus (HBV) reactivation during hepatitis C treatment have been reported. We analyzed serum samples from patients in a clinical trial of ledipasvir-sofosbuvir in Taiwan and Korea. Of the 173 patients enrolled, 103 (60%) had been previously infected with HBV. None showed evidence of HBV reactivation. ? The Author 2016.ALT flare; HBV reactivation; HCV/HBV coinfection[SDGs]SDG3alanine aminotransferase; hepatitis B core antibody; ledipasvir plus sofosbuvir; virus DNA; antivirus agent; benzimidazole derivative; fluorene derivative; ledipasvir; sofosbuvir; abnormal laboratory result; adult; aged; alanine aminotransferase blood level; antiviral therapy; Article; blood sampling; cohort analysis; combination drug therapy; compensated liver cirrhosis; controlled study; female; Hepatitis B virus; hepatitis C; human; Korea; major clinical study; male; multicenter study (topic); phase 3 clinical trial (topic); prevalence; priority journal; side effect; Taiwan; virus load; virus reactivation; clinical trial; combination drug therapy; complication; drug effects; hepatitis B; hepatitis C; middle aged; mixed infection; phase 3 clinical trial; virology; virus activation; Adult; Aged; Antiviral Agents; Benzimidazoles; Coinfection; Drug Therapy, Combination; Female; Fluorenes; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Male; Middle Aged; Sofosbuvir; Virus Activationjournal article10.1093/cid/ciw507274861122-s2.0-84994500704